10 Best Cosmetic Surgery and Aesthetics Stocks To Buy

5. Bausch Health Companies Inc. (NYSE:BHC)

Number of Hedge Fund Investors: 34

A global pharmaceutical company, Bausch Health Companies Inc. (NYSE:BHC) operates in the fields of dermatology and cosmetic medicine. Through its majority ownership in Bausch & Lomb, it creates, produces, and sells a range of products. The firm provides skin care products, dermal fillers, and minimally invasive procedures, among other cosmetic products and aesthetic treatments.

A legal investigation into price-rigging caused Bausch Health Companies Inc.’s share price to plummet by more than 97% from its 2015 peak. Rumors of bankruptcy caused the stock to plunge 43% in July, from $7.50 to $4.30 a share, before rising to $5.82 when the firm refuted the reports. Although Salix and Bausch + Lomb, two of the company’s key segments, performed well in the first quarter of 2024, worries are raised by Bausch’s large debt, which is presently $21.5 billion, and by the Xifaxan patent issues.

Although sales increased by 10.75% to $2.15 billion in the first quarter of 2024 over the same period the previous year, controlling net debt remained difficult. Since Bausch has a lot of debt and is still in litigation, Fitch Ratings recently lowered the company’s financial standing, indicating instability in the company’s finances and uncertainty about its future.

Nonetheless, Stifel has adjusted the price objective for the company from $10.00 to $6.00, indicating the possibility of a comeback bolstered by increased profit margins and decreased cash burn. The company has $947 million in cash and cash equivalents, up 67.91% year over year. Shares sport a consensus Buy and the average price target of $10.5 implies an upside of 75.29% from current levels.

Bausch Health Companies Inc. (NYSE:BHC) is one of the best cosmetic surgery and aesthetics stocks to buy. 34 hedge funds owned Bausch Health Companies Inc. (NYSE:BHC) in Q1 2024. Carl Icahn’s Icahn Capital LP is the largest stakeholder in the company, with 34,721,118 shares worth $368.39 million.